海隆控股(01623.HK)拟发行2亿美元优先票据
格隆汇9月20日丨海隆控股(01623.HK)公布,公司已把最高接纳金额定于2亿美元,并决定接纳全部有效呈交的2020年票据。公司接纳购买每1,000美元本金额的202年票据购买价为1,003.75美元。
因此,根据要约条款,公司将支付:(i)就接纳购买所有该等2020年票据的总购买价145,429,332.50美元;及(ii)产生的合计应计利息,款额为2,742,772.46美元。
此外,公司将发行2亿美元于2022年到期8.25厘优先票据。票据要约价将为票据本金额的99.480%。公司拟把同步新资金发行的所得款项净额主要用于为现有离岸债务再融资,以及作为营运资金及供一般企业用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.